Company intelligence / Profile preview

Hologen Neuro AI Limited

Channel Islands, Guernsey

Ownership: Private
Development stage: Other

Overview

AAV-GAD gene therapy for Parkinson’s showed 18-point UPDRS Part 3 improvement in Phase II high-dose arm at 26 weeks, with QoL benefits; preparing Phase III mid-2025. Hologen’s AI analyzed data for disease-modifying brain changes.[2][3]

Therapeutic areas: EndocrinologyNeurology
Modalities: Gene therapy
Industry: Biotech

Partnerships

MeiraGTx (joint venture partner, 30% ownership, clinical/manufacturing lead)

Beyond the preview

Go deeper on Hologen Neuro AI Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hologen Neuro AI Limited.

Explore the full profile